May 18, 2022 8:00am EDT Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
May 11, 2022 7:00am EDT Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 04, 2022 8:00am EDT Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
Mar 01, 2022 7:00am EST Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
Feb 23, 2022 8:00am EST Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
Jan 14, 2022 8:00am EST Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
Jan 03, 2022 7:00am EST Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
Nov 08, 2021 8:00am EST Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
